Jim Cramer says one stock hitting new highs is still a screaming buy
Jim Cramer reiterated a triple buy call on Hinge Health (HNGE) on “Mad Money” Aug. 11. The stock hit a new all-time high of $93.13 on Aug. 10 and is up about 85.83% YTD, per Yahoo Finance. Hinge reported Q2 2026 revenue of $213 million (+53% YoY), free cash flow of $99.6 million, and raised FY guidance to $856-$860 million. It also agreed to a $105 million cash acquisition (Cylinder Health) to expand into GI care.
How this was made
The 30-second read
Why it matters
For traders, the actionable elements are the specific financial metrics and corporate actions cited: Q2 revenue growth, free cash flow tripling, guidance raises, the $105M cash acquisition for GI care, and a $300M buyback authorization increase.
Market read
The article ties together multiple catalysts that can sustain momentum in Hinge Health: leverage in Q2, raised full-year and Q3 revenue guidance, and expansion via acquisition alongside increased repurchases.
What to watch
Integration risk from the Cylinder Health acquisition, potential reimbursement or employer-plan adoption variability, and the possibility that margin expansion could normalize after near-term growth investments.
Background
The piece is a Cramer-driven spotlight on Hinge Health, citing its Q2 2026 performance, raised guidance, and expansion moves (migraine program and GI acquisition).
Ticker impact
Hinge Health reported Q2 2026 results with revenue up 53% YoY to $213M, raised full-year guidance, and announced a $105M GI acquisition plus a larger buyback.
Near-term upside bias as traders price in guidance raises, acquisition-driven expansion, and buyback support; volatility likely given the stock’s large YTD run.
The text provides specific, time-stamped fundamentals (Aug 4 results, Aug 10 all-time high, same-day acquisition confirmation, July 29 buyback increase) that can drive incremental positioning, though it is framed as Cramer commentary rather than fresh primary disclosure beyond the cited events.
Market effects
Supports the narrative that enterprise-focused digital health platforms can scale margins and expand into adjacent care categories (MSK to migraine and GI).
No clear regional-specific impact beyond US-listed growth/healthcare sentiment.
Limited direct global spillover; primarily a US digital health and healthcare services read-through.
Counterpoint
The article is promotional and anchored to Cramer’s framing; the stock’s large YTD move may already discount the acquisition and guidance, increasing downside risk if execution or adoption slows.
Key entities
- companyHinge Health
AI-powered digital MSK care provider expanding into migraine and gastrointestinal care; reported Q2 2026 results and raised guidance, plus announced a $105M acquisition and buyback increase.
